Therapeutic drug monitoring of posaconazole: watch-out for gastrointestinal graft-versus-host disease.

Antimicrob Agents Chemother. 2012 Jul 30. [Epub ahead of print]

Therapeutic drug monitoring of posaconazole: watch-out for gastrointestinal graft-versus-host disease.

Source

Pharmacology and Toxicology Laboratory, Department of Biochemistry, Toxicology and Pharmacology, University Hospital Grenoble.

Abstract

Posaconazole (PCZ) is the latest triazole antifungal agent that has been approved for prophylaxis of invasive aspergillosis in high-risk immunocompromised patients, such as allogeneic hematopoietic stem cell transplantation patients, who develop graft-versus-host disease (GVHD). PCZ has high interindividual variability with regard to its plasma trough concentrations (C(min)). Moreover the concentration-efficiency relationship remains to be better characterized in prophylaxis. To determine the variability factors in plasma concentrations, PCZ C(min) and clinical parameters (localization of GVHD, presence of diarrhea, and diagnosis of invasive aspergillosis) were collected retrospectively in 29 consecutive allogeneic hematopoietic stem cell transplantation patients who developed GVHD and were receiving prophylactic PCZ (200 mg 3 times/day ≥ 7 days). Blood samples were analyzed at steady state to determine PCZ C(min) by liquid chromatography-tandem mass spectrometry. The average PCZ C(min) value was 1.28±0.82 mg/L (n= 292 dosages), with an intraindividual variability of 49% and an interindividual variability of 64%. Twenty percent of C(min) values were below 0.7 mg/L, which is considered the threshold of efficacy by the Food and Drug Administration. Patients who suffer from gastrointestinal (GI) GVHD experienced a 24% reduction in posaconazole C(min) compared with other localizations of GVHD. This decrease reached 33% when patients presented with diarrhea due to GI GVHD or an infectious etiology. PCZ C(min) values were 26% lower when invasive aspergillosis was declared. These data demonstrate that GI disturbances affect drug concentrations. Thus, therapeutic monitoring of PCZ can be used to detect low drug concentrations, possibly resulting in a lack of efficacy of invasive aspergillosis prophylaxis.

PMID:
22850515
[PubMed – as supplied by publisher]

 

Deja un comentario

Este sitio usa Akismet para reducir el spam. Aprende cómo se procesan los datos de tus comentarios.